Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of “Moderate Buy” from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $48.38.

Several research analysts recently commented on the company. Barclays boosted their price target on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Oppenheimer reissued an “outperform” rating and set a $59.00 price objective (up from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. Finally, HC Wainwright increased their price target on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, COO Seshadri Neervannan sold 4,879 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the completion of the transaction, the chief operating officer now owns 64,767 shares in the company, valued at $1,981,870.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the transaction, the general counsel now owns 40,951 shares in the company, valued at approximately $1,253,100.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Seshadri Neervannan sold 4,879 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $149,297.40. Following the completion of the transaction, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,496 shares of company stock worth $749,578. 11.54% of the stock is owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently bought and sold shares of TARS. China Universal Asset Management Co. Ltd. raised its position in shares of Tarsus Pharmaceuticals by 362.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock worth $78,000 after buying an additional 3,004 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Tarsus Pharmaceuticals by 22.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock worth $92,000 after purchasing an additional 824 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Tarsus Pharmaceuticals by 65.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after purchasing an additional 2,092 shares during the period. Nations Financial Group Inc. IA ADV bought a new position in Tarsus Pharmaceuticals during the 1st quarter valued at $218,000. Finally, Simplicity Wealth LLC bought a new position in Tarsus Pharmaceuticals during the 1st quarter valued at $223,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 2.8 %

NASDAQ TARS opened at $32.76 on Thursday. The company has a quick ratio of 6.85, a current ratio of 6.93 and a debt-to-equity ratio of 0.15. Tarsus Pharmaceuticals has a fifty-two week low of $12.57 and a fifty-two week high of $40.40. The business has a 50 day moving average price of $33.98 and a two-hundred day moving average price of $24.69. The stock has a market cap of $1.12 billion, a PE ratio of -7.06 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $4.63 million. During the same quarter last year, the company posted ($0.49) earnings per share. As a group, sell-side analysts predict that Tarsus Pharmaceuticals will post -4.25 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.